17p deletion strongly influences rituximab elimination in chronic lymphocytic leukemia

Chronic lymphocytic leukemia (CLL) is the most common type of leukemia and the anti-CD20 monoclonal antibody, rituximab, represents the therapeutic gold standard for more than 2 decades in this pathology, when used in combination with chemotherapy. However, some patients experience treatment resista...

Descripción completa

Detalles Bibliográficos
Autores principales: Bagacean, Cristina, Tempescul, Adrian, Ternant, David, Banet, Anne, Douet-Guilbert, Nathalie, Bordron, Anne, Bendaoud, Boutahar, Saad, Hussam, Zdrenghea, Mihnea, Berthou, Christian, Paintaud, Gilles, Renaudineau, Yves
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6352369/
https://www.ncbi.nlm.nih.gov/pubmed/30696487
http://dx.doi.org/10.1186/s40425-019-0509-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6352369/
https://www.ncbi.nlm.nih.gov/pubmed/30696487
http://dx.doi.org/10.1186/s40425-019-0509-0

Ejemplares similares